ODDITY Tech (ODD) Stock

Earlier this year FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart disease Earlier this year FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart disease

Oddity Tech's data-driven, AI-powered DTC model looks set to facilitate market share gains through FY28. ODD's forward EV/EBITDA valuation of 16.2x is pricier than the industry average, but we feel it is worth this premium, considering the superior EBITDA profile of the business. ODD's robust balance sheet, zero debt, and strong free cash flow support have prompted a shift towards share buyback momentum with another $100m yet to be deployed.

From a technical perspective, Oddity Tech (ODD) is looking like an interesting pick, as it just reached a key level of support. ODD recently overtook the 20-day moving average, and this suggests a short-term bullish trend.

Oddity Tech (ODD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (NASDAQ: ODD) today announced that it has entered into a transaction with a fund managed by L Catterton (“L Catterton”) to repurchase approximately 2.35 million Class A Ordinary Shares (the “Shares”) of the Company for a total cash consideration of approximately $100 million, at a purchase price of $42.501 per share. The transaction will be funded from the Company's existing cash resources.

Oddity Tech Ltd (NASDAQ:ODD ) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Maria Lycouris - Investor Relations Oran Holtzman - Co-Founder and Chief Executive Officer Lindsay Drucker Mann - Global Chief Financial Officer Conference Call Participants Dara Mohsenian - Morgan Stanley Nick Cronin - Truist Securities Operator Good morning, and welcome to the ODDITY's Third Quarter 2024 Earnings Conference Call. Today's call is being recorded, and we have allocated time for prepared remarks and Q&A.

Oddity Tech (ODD) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.21 per share a year ago.

LOS ANGELES, CA / ACCESSWIRE / September 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Oddity Tech Ltd. ("Oddity" or "the Company") (NASDAQ:ODD) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

NEW YORK, NY / ACCESSWIRE / September 17, 2024 / If you suffered a loss on your ODDITY Tech Ltd. (NASDAQ:ODD) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/oddity-tech-lawsuit-submission-form?prid=103340&wire=1 or contact Joseph E.